Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; iron oxide yellow; hypromellose - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisone, quantity: 1 mg - tablet, uncoated - excipient ingredients: crospovidone; lactose monohydrate; povidone; magnesium stearate; maize starch - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; andrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone, quantity: 1 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; povidone; lactose monohydrate; crospovidone - wherever corticosteroid therapy is indicated such as: pemphigus vulgaris, allergic dermatitis, eczema, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; andrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, acute leukaemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout, periarthritis of the shoulder.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; iron oxide yellow; hypromellose - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; water for injections - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy ondersertron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 17.857 mg (equivalent: darifenacin, qty 15 mg) - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000; iron oxide yellow; iron oxide red - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - darifenacin hydrobromide, quantity: 8.929 mg (equivalent: darifenacin, qty 7.5 mg) - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; calcium hydrogen phosphate; titanium dioxide; purified talc; macrogol 4000 - enablex prolonged-release tablets are indicated for the treatment of overactive bladder, with the symptoms of urgency, urge urinary incontinence or frequency of micturition.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: povidone; sodium lauryl sulfate; saccharin sodium; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; maize starch; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: saccharin sodium; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; povidone; magnesium stearate; maize starch; lactose monohydrate; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 300 mg (equivalent: cefuroxime, qty 250 mg) - suspension, powder for - excipient ingredients: povidone; sucrose; stearic acid; flavour - zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.